AbbVie Inc. closed 17.25% short of its 52-week high of $207.32, which the company achieved on October 31st.

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.